The Business of Anti-Aging Science

Magalhães, João Pedro de; Stevens, Michael T.; Thornton, Daniel

doi:10.1016/j.tibtech.2017.07.004

Cited by 139 publications

(98 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aging cells accumulate DNA damage, where the cell cycle checkpoints plan for an irreversible growth arrest. 68 Along with this, advances in metagenomics have shown that the majority of Earthʼs biodiversity has not been explored for natural products discovery yet. The extract of S. flavida prompted a reduction in the proportion of the cells in the G0/G1 phase and increased the number of G2/M cells, which clearly showed that the rate of cell division was accelerated.…”

Section: Discussionmentioning

confidence: 99%

Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells

Momtaz

Baeeri

Rahimifard

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Aging contributes to an increased risk of developing a number of neurodegenerative and chronic disorders, predominantly related to oxidative stress (OS) and defects in the antioxidant balance. This study focused on the antisenescence effect of four plant species (Falcaria vulgaris, Ixiolirion tataricum, Ajuga chamaecistus, and Scabiosa flavida) on H2O2‐induced premature senescence in rat NIH3T3 fibroblasts, which were found to be rich in effective phytochemicals with traditional ethnobotanical backgrounds. Plant materials were collected, identified, and extracted. To determine the viability of NIH3T3 cells, an MTT assay was conducted. The levels of OS markers and the senescence‐associated ß‐galactosidase (SA‐ß‐GAL) activity were analyzed by the Elisa reader. The cell cycle pattern was evaluated by flow cytometry. The expression of senescence‐related inflammatory cytokines and the molecules involved in aging signaling pathways were investigated using the real‐time reverse transcription polymerase chain reaction (RT‐PCR). H2O2 treatment decreased cell viability and increased lipid peroxidation (LPO) and the reactive oxygen species (ROS) in NIH3T3s. However, S. flavida exhibited low cytotoxicity, reduced OS and SA‐ß‐GAL activities in NIH3T3 cells compared with the H2O2‐treated group. I. tataricum was the second best plant, although it was more toxic to NIHT3T cells. S. flavida decreased G0/G1 arrest and facilitated the G2/M transition of NIH3T3s, also downregulated the expression of p38, p53, p16, and the related inflammatory mediators. S. flavida potentially modulated senescence‐associated hallmarks in fibroblasts exposed to H2O2, thus it may inhibit the aging process via controlling the OS. Therefore it is a promising candidate for future antiaging explorations.

show abstract

Section: Discussionmentioning

confidence: 99%

Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells

Momtaz

Baeeri

Rahimifard

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Identifying rejuvenating factors in human blood has resulted in significant optimism for finding simple and affordable treatments for age-related diseases [21]. However, so far, no convincing results have been presented, and no consensus on mechanisms or implications exists [10,14,20,22].…”

Section: Hofmannmentioning

confidence: 99%

Young Blood Rejuvenates Old Bodies: A Call for Reflection when Moving from Mice to Men

Hofmann

2018

Transfus Med Hemother

View full text Add to dashboard Cite

Connecting the circulatory system of old and young mice (parabiosis) is documented to have rejuvenating effects on cells, tissues, organs, and functions. A wide range of benefits are envisioned. Blood-based rejuvenation can come to totally change population health and aging. The first blood rejuvenation studies on humans with Alzheimer's disease have started. It puts blood at the center of therapy and revitalizes the historical line of humoral pathology from Hippocrates and Harvey, creating a new type of ‘bloodletting.' However, moving from mice to men requires careful consideration. Parabiosis actualizes well-known ethical challenges, such as just distribution of health care, avoiding disparities, and providing equal access to health care resources, as well as issues of human enhancement. However, it also poses new problems. Using internal substances in some persons as means to rejuvenate others calls for ethical reflection. New type of ‘blood bonds' may result from the continuous demand for specific types of blood. Even if rejuvenating substances from blood may be artificially and cheaply produced and justly distributed, problems arise: survival may have to be balanced against reproduction, as reproductive age increases. Eternal youth and endless bliss have always been vital human dreams. Although parabiosis may bring us closer to the fountain of youth than ever, it is still too early to provide full-fledged assessments of its implications or to foresee how it will change health, aging, medicine, and society. However, in order to bring our reflective abilities on par with our technical skills, we need to start reflection now.

show abstract

“…The pharmaceutical industry used to apply methods developed for single, acute diseases to multiple, chronic diseases (see Thiem et al 2011;Roman and Ruiz-Cantero 2017) instead of targeting the underlying aging and regenerative processes as described above. Since about 2015, various biotech companies have raised funds to bring biology of aging results to the clinics (see De Magalhães et al 2017;. Various investor reports, books, and conferences consider that current retired persons may be the first populations to benefit from such advances (see Mellon and Chalabi 2017;Pratt 2016;and Casquillas 2016).…”

Section: Solutions Derived From Biology Of Aging Are Reaching Clinicsmentioning

confidence: 99%

Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

Debonneuil

Eyraud-Loisel

Planchet

2018

Risks

View full text Add to dashboard Cite

Abstract:Pension funds, which manage the financing of a large share of global retirement schemes, need to invest their assets in a diversified manner and over long durations while managing interest rate and longevity risks. In recent years, a new type of investment has emerged, that we call a longevity megafund, which invests in clinical trials for solutions against lifespan-limiting diseases and provides returns positively correlated with longevity. After describing ongoing biomedical developments against ageing-related diseases, we model the needed capital for pension funds to face longevity risk and find that it is far above current practices. After investigating the financial returns of pharmaceutical developments, we estimate the returns of a longevity megafund. Combined, our models indicate that investing in a longevity megafund is an appropriate method to significantly reduce longevity risk and the associated economic capital need.

show abstract

The Business of Anti-Aging Science

Cited by 139 publications

References 65 publications

Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells

Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells

Young Blood Rejuvenates Old Bodies: A Call for Reflection when Moving from Mice to Men

Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

Contact Info

Product

Resources

About